Intravenous delivery of 5'-iododeoxyuridine during hyperfractionated radiotherapy for locally advanced head and neck cancers: Results of a pilot study

Laryngoscope

Volumn 108, Issue 7, 1998, Pages 1090-1094

  Epstein, Alan H ^a,c,d   Lebovics, Robert S ^b   Van Waes, Carter ^b   Smith, Judy ^c   Okunieff, Paul ^c   Cook, John A ^c  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cancer; Head; Neck; Radiation; Sensitizer

Indexed keywords

IDOXURIDINE; PYRIMIDINE DERIVATIVE; RADIOSENSITIZING AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; EYE TOXICITY; FEMALE; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG TOXICITY; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY; SALIVARY GLAND DISEASE; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IDOXURIDINE; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RADIATION DOSAGE; RADIATION-SENSITIZING AGENTS; REMISSION INDUCTION;

EID: 0031745291     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005537-199807000-00025     Document Type: Article

References (29)

1. Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 1996;88:890-9.
2. Wanebo HJ, Glicksman AS, Landman C, et al. Preoperative cisplatin and accelerated hyperfractionated radiation induces high tumor response and control rates in patients with advanced head and neck cancer. Am J Surg 1995;170:512-6.
3. Fu KK, Phillips TL, Silverberg IJ, et al. Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. J Clin Oncol 1987;5:1410-8.
4. Saunders MI, Dische S, Grosch EJ, et al. Experience with Chart. Int J Radiat Oncol Biol Phys 1991;21:871-8.
5. Al-Sarraf M, LeBlanc M, Giri PGS, et al. Improved overall survival with chemo-radiotherapy (CT-RT) vs radiotherapy (RT) in patients (PTS) with locally advanced nasopharyngeal cancer (NPC). Preliminary results of intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) randomized study. Proc 4th Int Conf Head Neck Cancer, Toronto, Canada; 1996 [p 118, abstract 240].
6. Cook JA, Glass J, Lebovics R, et al. Measurement of thymidine replacement in patients with high grade gliomas, head and neck tumors and high grade sarcomas after continuous infusions of 5-iododeoxyuridine. Cancer Res 1992;52:719-25.
7. Epstein AH, Cook JA, Goffman T, et al. Tumor radiosensitization with the halogenated pyrimidines 5′-bromo- and 5′-iododeoxyuridine. Br J Radiol 1992;24(suppl):209-14.
8. Iliakis G, Pantelias G, Kurtzman S. Mechanism of radiosensitization by halogenated pyrimidines: effect of BrdU on cell killing and interphase chromosome breakage in radiation-sensitive cells. Radiat Res 1991;125:56-64.
9. Iliakis G, Wright E, Ngo FQ. Possible importance of PLD repair in the modulation of Brd-Urd and IdUrd-mediated radiosensitization in plateau-phase C3H10T1/2 mouse embryo cells. Int J Radiat Biol Relat Stud Phys Chem Med 1987;51:541-8.
10. Iliakis G, Wright E, Ngo FQ. Repair and fixation of potentially lethal damage (PLD) as demonstrated by delayed plating or incubation with araA in contact inhibited plateau-phase C3H mouse embryo 10 T1/2 cells grown in the presence of BrdUrd. Radiat Environ Biophys 1987;26:47-62.
11. Bagshaw MA, Doggett RL, Smith KC, et al. Intra-arterial 5- bromodeoxyuridine and x-ray therapy. Am J Roentgenol 1967;99:886-94.
12. Goffman T, Tochner Z, Glatstein E. Primary treatment of large and massive adult sarcomas with iododeoxyuridine and aggressive hyperfractionated irradiation. Cancer 1991;67:572-6.
13. Sullivan FJ, Herscher LL, Cook JA, et al. National Cancer Institute (Phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: results in anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1994;30:583-90.
14. Kinsella TJ, Collins J, Rowland J, et al. Pharmacology and phase I/II study of continuous intravenous infusions of iododeoxyuridine and hyperfractionated radiotherapy in patients with glioblastoma multiforme. J Clin Oncol 1988;6:871-9.
15. Goffman TE, Dachowski LJ, Bobo H, et al. Long-term follow-up on National Cancer Institute Phase I/II study of glioblastoma multiforme treated with iododeoxyuridine and hyperfractionated irradiation. J Clin Oncol 1992;10:264-8.
16. Epstein AH, Lebovics RS, Goffman T, et al. Treatment of locally advanced cancer of the head and neck with 5′-iododeoxyuridine and hyperfractionated radiation therapy: measurement of cell labeling and thymidine replacement. J Natl Cancer Inst 1994;86:1775-80.
17. Phillips TL, Bodell WJ, Uhl V, et al. Correlation of exposure time, concentration and incorporation of IdUrd in V-79 cells with radiation response. Int J Radiat Oncol Biol Phys 1989;16:1251-5.
18. Lawrence TS, Davis MA, Maybaum J, et al. The dependence of halogenated pyrimidine incorporation and radiosensitization on the duration of drug exposure. Int J Radiat Biol Oncol Phys 1990;18:1393-8.
19. Rodriguez R, Ritter MA, Fowler JF, et al. Kinetics of cell labeling and thymidine replacement after continuous infusion of halogenated pyrimidines in vivo. Int J Radiat Oncol Biol Phys 1994;29:105-13.
20. Suit HD. Theoretical evaluation of a limitation in the use of pyrimidine analogs in radiation therapy. Radiology 1966;86:1065-8.
21. Pajak TF, Laramore GE, Marcial VA, et al. Elapsed treatment days - a critical item for radiotherapy quality control review in head and neck trials: RTOG report. Int J Radiat Oncol Biol Phys 1991;20:13-20.
22. Withers HR, Taylor JM, Maciejewski B. The hazards of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988;27:131-46.
23. Adelstein DJ, Saxton JP, Van Kirk MA, et al. Continuous course radiation therapy and concurrent combination chemotherapy for squamous cell head and neck cancer. Am J Clin Oncol 1994;17:369-73.
24. Shanta V, Krishnamurthi S. Combined bleomycin and radiotherapy in oral cancer. Clin Radiol 1980;31:617-20.
25. Vokes EE, Panje WR Schilsky RL, et al. Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study. J Clin Oncol 1989;7:761-8.
26. Harrison LB, Raben A, Pfister DG, et al. A prospective phase II trial of concomitant chemotherapy and radiotherapy with delayed accelerated fractionation in unresectable tumors of the head and neck. Proc 4th Int Conf Head Neck Cancer, Toronto, Canada, 1996; [p 102, abstract 175].
27. Kies MS, Haraf DJ, Mittal B, et al. Analysis of induction chemotherapy with cisplatin, 5-FU, leucovorin (or the L stereoisomer-L() and (-interferon-2B (PFL() followed by 5-FU, hydroxyurea and radiation (FHX) (PFL((FHX) in high-risk stage III and stage IV head and neck cancer. Proc 4th Int Conf Head Neck Cancer, Toronto, Canada; 1996 [p 101, abstract 169].
28. Lutz RJ, Epstein AH, Cook JA, et al. An in vitro flow model to study streaming during pelvic intra-arterial drug infusions. Gynecol Oncol 1995;59:288-96.
29. Lutz RJ, Dedrick RL, Boretos J, et al. Mixing studies during intracarotid artery infusions in an in vitro model. J Neurosurg 1986;64:277-83